Efficient tumor targeting by single-domain antibody fragments of camels

International Journal of Cancer

Volumn 98, Issue 3, 2002, Pages 456-462

  Cortez Retamozo, Virna ^a   Lauwereys, Marc ^a   Hassanzadeh Gh , Gholamreza ^a   Gobert, Martine ^a   Conrath, Katja ^a   Muyldermans, Serge ^a   De Baetselier, Patrick ^a   Revets, Hilde ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Affinity; Camel antibodies; Lysozyme; Single domain antibodies; Tumor targeting

Indexed keywords

ANTIBODY; EPITOPE; LYSOZYME; PROTEIN CAB LYS2; PROTEIN CAB LYS3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY AFFINITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING SITE; CAMEL; CIRCULATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; METASTASIS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; TISSUE DISTRIBUTION; TUMOR;

ANIMALS; ANTIBODY AFFINITY; CAMELS; CARCINOMA, LEWIS LUNG; CYTOKINES; EPITOPES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; MICE, SCID; MURAMIDASE; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037139394     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10212     Document Type: Article

References (35)

1. The development of monoclonal antibodies for the therapy of cancer
2. Recombinant antibody fragments
3. Single-chain antigen-binding proteins
4. Recombinant antibody constructs in cancer therapy
5. An improved linker for scFv with reduced aggregation and enhanced proteolytic stability
6. Naturally occuring antibodies devoid of light chains
7. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies
8. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies
9. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies
10. Single domain antibodies: Comparison of camel VH and camelised human VH domains
11. Redefining the minimal antigen-binding fragment
12. Mix and match: Building manifold binding sites
13. Camel single-domain antibodies as modular building units in bispecific and bivalent constructs
14. Experimental analysis of the metastatic phenotype of malignant leukocytes
15. Characterization of 3LL-Tumor variants generated by in vitro macrophage-mediated selection
16. Comparison of llama VH sequences from conventional and heavy-chain antibodies
17. Anatomy of the antibody molecule
18. 131I-labeled Hepama-1 mAb. Preliminary results and discussion
19. 131I-Lym-1
20. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A
21. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment With an anti-CD16 bispecific antibody
22. Isolation of picomolar affinity anti-c-erB2 single-chain Fv by molecular evolution of the complementarity determining regions in the centre of the antibody combining site
23. Binding activities of a repertoire of single immunoglobulin variable domains secreted from E. coli
24. Camelizing human antibody fragments: NMR studies on VII domains
25. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains
26. Isolation of high affinity human antibodies directly from large synthetic repertoires
27. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library
28. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies
29. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
30. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis
31. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human IIER-2/neu
32. Therapeutic effects of monoclonal antibody-β-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma
33. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules
34. A modeling analysis of monoclonal antibody percolation through tumors: A binding site barrier
35. Isolation of antigen-specific llama VHH antibody fragment and their high level secretion by Saccharomyces cerevisiae